Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

Incyte (INCY) and Calithera Biosciences (CALA) Enter Pact to Develop and Commercialize CB-1158

January 30, 2017 6:49 AM EST

Incyte Corporation (NASDAQ: INCY) and Calithera Biosciences, Inc. (NASDAQ: CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calitheras first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology. CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination with immuno-oncology agents, including anti-PD-1... More

Incyte (INCY), Calithera Biosciences (CALA) Enter Collaboration to Develop and Commercialize CB-1158

January 30, 2017 6:48 AM EST

Incyte Corporation (NASDAQ: INCY) and Calithera Biosciences, Inc. (NASDAQ: CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calitheras first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology. CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination with immuno-oncology agents, including anti-PD-1 therapy.

Arginase-expressing... More